Gensia Inc. (GNSA)
Richard Stover of Stover Haley Burns said he remains optimistic regarding the regulatory review of GNSA's Protara (Arasine), despite the company's announcement earlier this month that the FDA won't review the drug for reducing cardiac complications in coronary artery bypass graft (CABG) surgery until a third Phase III trial is completed. Stover still expects commercial introduction of Protara in the U.S. in late 1994 or the first half of 1995.